Update information
February 2017: Statement 1 has been updated to reflect changes made to the NICE guideline on recent-onset chest pain.
Definitions for statement 3 have also been updated to include Medicines and Healthcare products Regulatory Agency (MHRA) advice about ivabradine and nicorandil.
January 2013: Licensing information for nicorandil has been updated.